Leerink: 'We continue to recommend REGN shares'

Regeneron Pharma (REGN) PT Raised to $753 at Bernstein SocGen Group

August 4, 2025 9:22 AM EDT

Bernstein SocGen Group analyst William Pickering raised the price target on Regeneron Pharma (NASDAQ: REGN) to $753.00 (from $750.00) while maintaining an Outperform rating.

The analyst commented: "Regeneron delivered a very strong quarter by the numbers but also annoucned a fresh round of regulatory... More

Regeneron Pharma (REGN) PT Raised to $761 at Morgan Stanley

August 4, 2025 8:35 AM EDT

Morgan Stanley analyst Matthew Harrison raised the price target on Regeneron Pharma (NASDAQ: REGN) to $761.00 (from $754.00) while maintaining a Overweight rating.... More

Regeneron Pharma (REGN) PT Raised to $815 at Guggenheim

August 4, 2025 5:53 AM EDT

Guggenheim analyst Yatin Suneja raised the price target on Regeneron Pharma (NASDAQ: REGN) to $815.00 (from $810.00) while maintaining a Buy rating.

The analyst comments "Key Message: REGN 2Q performance came in above investor expectations on strong Dupixent sales and a good performance from a struggling Eylea franchise, which has been impacted by both competitive pressures and persistent regulatory... More

Regeneron Pharma (REGN) PT Lowered to $780 at TD Cowen

August 1, 2025 1:01 PM EDT

TD Cowen analyst Tyler Van Buren lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $780.00 (from $800.00) while maintaining a Buy rating.... More

Regeneron (REGN) Tops Q2 EPS by 439c

August 1, 2025 7:10 AM EDT

Regeneron (NASDAQ: REGN) reported Q2 EPS of $12.89, $4.39 better than the analyst estimate of $8.50. Revenue for the quarter came in at $3.68 billion versus the consensus estimate of $3.29 billion.

For earnings history and earnings-related data on Regeneron (REGN) click here.

... More

Trump demands pharma CEOs lower drug prices within 60 days

July 31, 2025 2:02 PM EDT

Investing.com -- President Donald Trump has sent letters to the CEOs of 17 pharmaceutical companies demanding action to address high prescription drug costs in the United States, the White House announced Thursday.

Trump shared the letters sent to major pharmaceutical firms including Regeneron (NASDAQ: REGN), Merck (NSE:PROR), AstraZeneca (NASDAQ: AZN), GSK,... More

Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social

July 31, 2025 1:38 PM EDT

(Updated - July 31, 2025 1:49 PM EDT)

U.S. President Donald Trump has posted letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social on Thursday.

Here's the text of the letter (from the letter sent to Novo Nordisk):

On May 12, 2025, I signed an Executive OrderDelivering Most-Favored-Nation Prescription Drug Pricing to American Patientsto stop global freeloading and guarantee that Americans pay the same prices enjoyed by other developed nations. Right now, brand name drug prices in the United States are up to three times higher on average... More

White House: Trump took action on pharma Thursday, sent letters to CEOs

July 31, 2025 1:33 PM EDT

(Updated - July 31, 2025 1:38 PM EDT)

White House: Trump took action on pharma Thursday, sent letters to CEOs

White House: letters sent to 17 major drug and pharma companies in U.S.White House: Trump tells pharma execs to extend most favored nation pricing to Medicaid,... More

Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)

July 31, 2025 9:00 AM EDT

Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $678.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst commented, "Sanofi reported Q2 results this morning giving us a first look into Dupixents (Dupi) sales performance (partnered with Regeneron) ahead of... More